At the beginning of 2010 DNA fragments of a porcine circovirus 1 (PCV-1) were detected in the monovalent rotavirus vaccine, Rotarix® (GlaxoSmithKline), and later also of PCV-1 and PCV-2 in the RotaTeq® (MSD) vaccine. These viruses are frequently found in meat and other products for normal human consumption and have not been shown to cause disease in humans. Although the World Health Organization (WHO) and the European Medicines Agency (EMA) did not recommended discontinuation of vaccination against rotavirus because of its positive risk- benefit ratio, the Spanish Medicines and Health Products Agency (AEMPS) did not authorize the release of new batches of Rotarix® and RotaTeq® vaccines onto the Spanish market since March 29 and June 10, 2010, respectively, due to problems of good manufacturing practice (GMP), until research on this issue was complete.1 On November 4, 2010, AEMPS again allowed the release of batches of the RotaTeq® vaccine having checked that it only had fragments of the DNA of the porcine virus (and thereby met the GMP standards), so that currently there are only restrictions on the marketing of the Rotarix® vaccine.1 Until March 2010, the average vaccination coverage against rotavirus in Spain in terms of dose distribution data (BMI and census data) had reached 40%. Furthermore, the first data reported on the effectiveness of the vaccine in Spain were consistent with this coverage and with the data reported for other countries.2,3